Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My post to Dr. Woodcock:
Dr. Woodcock,
I am writing to ask for your support for Leronlimab as a therapeutic for Covid-19
Although Leronlimab did not meet its primary endpoint of fatalities at 28 days, in a Phase 3 trial, it did show dramatic improvement in the current standard of care.
This latest trial also established, with statistical significance, that Covid patients got out of the hospital six days sooner with Leronlimab than with the SOC.
Finally, treatment in over 1,000 patients has demonstrated that Leronlimab has no toxicity, and no serious adverse events.
You previously expressed your support for any drugs that improved upon the SOC for Covid-19, regardless of its P value.
I support that pragmatic approach, while we continue to battle Covid-19, and its variants. I would therefore urge you to support an EUA for Leronlimab, while further trials continue.
I close with this question:
If you or a loved one became infected with Covid-19, and were intubated as a result, would you not want to have the option to use a safe drug that has proven to reduce both mortality, and the length of hospitalization?
Unless you cannot honestly answer "no" to this question, it is important that Leronlimab be made available now, before further lives are lost.
Thank you for taking the time to read, and consider, these thoughts.
Get BlueMail for Android
?Get TypeApp for Android ?
Perhaps it's just me, but I will take the word of Dr. Kastelein, perhaps the world's foremost authority on lipid cardiology, over paid bashers and shorts.
According to Dr. Kastelein, the most significant factor lipid factor in reducing cardiac events (CE) is the level of EPA in the blood.
On this count, MAT 9001 again handily bested Vascepa for the second time.
Moreover, in the per protocol (PP) group, MAT 9001 showed clinically significant improvement over Vascepa in reducing triglycerides, along with many other lipid markers. This is especially significant as the PP group consists of those patients who actually took the drug as prescribed rather than those who are less careful about doing so.
Presumably, if a patient does to the trouble of getting a prescription for MAT 9001, he/she would take it as prescribed. If so, he/she will have much higher EPA blood levels, and much lower triglycerides than if he/she had taken Vascepa.
More significantly, given the higher level of EPA in the blood, it stands to reason those patients taking MAT 9001 will have a significantly greater reduction in cardiac events than the 25% reduction in CE shown for those patients taking Vascepa.
My opinions, of course, but they would seem to be supported by the trials to date, along with the opinions of prominent scientists and cardiologists, including Dr. Kastelein.
Brilliant acquisition of Upright that further differentiates DRIO from competitors such as Livongo.
Market has not yet appreciated the value of adding the leading MSK platform to DRIO's own platform.
The concurrent investment by leading bioscience institutional investors, such as Perceptive, at market price, is also very positive news, and further validates the value and potential of this company.
Lypdiso is the brand name for MAT 9001, that is now in a second head to head trial vs. Vascepa, with topline results to be announced in 1Q 21. I expect such results to again show that MAT 9001 is far superior to Vascepra in lowering triglycerides, PCSK9, and various other lipid markers.
Also in the MTNB pipeline are (1) MAT 2203 (LNC version of amphotericin b), which is now in a Phase 2 trial for cryptococcal meningitis, fully funded and sponsored by the NIH, and (2) MAT 2205 (LNC version of amikacin), which has funding for research from the Cystic Fibrosis Foundation.
Of course, the LNC platform can potentially make many more effective, but highly toxic, drugs, safe and effective, which is why five big pharmaceutical companies are now in collaborations with MTNB to encochleate their drugs.
Best of luck, and happy New Year, to you and all of our shareholders.
LM
The woman who reads the questions at the end of the shareholder calls is Arian Colachis.
I would suggest we shareholders submit the following two questions to Cytodyn to be answered at the upcoming shareholder call in the question and answer session:
Can you explain why Dr. Pourhassan, Dr. Kelly, and Mike Mulholland recently sold stock which netted them, collectively, more than $20 million at a time Dr. Pourhassan was telling shareholders the stock price should be in triple digits?
Can you explain why during the entire time he has been president of Cytodyn, Dr. Pourhassan has not purchased any stock, other than by exercising options or warrants that netted him $12 million?
$4 price target by BTIG's 5 star analyst, Robert Hazlett, helps, but it is old news.
What is more important are the reasons given by Hazlett for his $4 price target:
1. Ongoing LNC trials funded by the NIH and CF Foundation;
2. Soon to be announced results from a second head to head trial of MAT 9001 vs. Vascepa, with results expected to strongly favor MAT 9001; and
3. Collaborations with 5 big pharmaceutical companies, any one of which could choose to purchase MTNB at a huge premium for what would be a pittance for any of these companies.
Short term catalysts abound from top line results for the MAT 9001's second head to head trial vs. Vascepa in 1Q 21, to the DMSC approval for next cohort progression for the MAT 2203 (LNC version of amphotericin b) Phase 2 trial for cryptococcal meningitis in 2Q 21. In addition, the MF Foundation has funded a trial for MAT 2501 (LNC version of amikacin) that should commence soon. Five big pharmaceutical companies, who have entered into collaborations with MTNB show confidence in the company, and its LNC platform.
As for funds, the company has cash on hand sufficient to fund operations through mid-2023. As such, no raise will be needed before major milestones are achieved.
Results from the second head to head trial of MAT 9001 vs Vascepa will be announced in 1Q 2021. If, as expected, MAT 9001 again proves to be much more effective than Vascepa in lowering triglycerides, and PCSK9 levels, that alone should boost the price at least 3X.
Then there are the ongoing trials for the LNC formulations of amphotericin b and amikacin, that are being funded by the NIH and CF Foundation, respectively, either of which, if successful, could catapult the SP of the stock.
And of course, MTNB is in collaboration with numerous BP companies including Gilead, Sanofi, and Regeneron, each of which has asked MTNB to encochleate their drugs to make them safer and orally available.
If even one of these BP trials proves to be successful, MTNB could be acquired at a huge premium to its current SP.
Management comes from BP, including its chairman, Herb Conrad, who was president of Roche, and know how to get drugs approved, and a company sold.
Correction of last post:
Whatever the reason for the EOY drop, catalysts abound in the coming 6 months including topline results for MAT 9001's head-to-head trial vs. Vascepa, and DSMC authorization to dose the next cohort of patients in the NIH funded MAT 2203 trial for the LNC version of amphotericin b.
The muscular dystrophy foundation funded study of MAT 2501--the LNC version of amikacin--and results from numerous collaborations with BP, including Gilead, Sanofi, and Regeneron, also loom on the horizon.
Note that Matinas' market cap is only a fraction of Amarin, whose primary product, Vascepa, I expect will soon be shown to be far less effective than MAT 9001 in reducing triglycerides.
Also note that Matinas' market cap is only a fraction of that of Insmed whose primary product is an inhalable version of amikacin I expect will soon be shown to be more toxic, and less effective, than MAT 2202, which is an oral LNC version of this drug.
Led by a strong management team, I fully expect Matinas to trade at many multiples of its current SP in 2021.
LM
Whatever the reason for the EOY drop, catalysts abound in the coming 6 months including topline results for MAT 9001's head-to-head trial vs. Vascepa, and DSMC authorization to dose the next cohort of patients in the NIH funded MAT 2203 trial for the LNC version of amphotericin b.
The muscular dystrophy foundation funded study of MAT 2501--the LNC version of amikacin--and results from numerous collaborations with BP, including Gilead, Sanofi, and Regeneron, also loom on the horizon.
Note that Matinas' market cap is only a fraction of Amarin, whose primary product, Vascepa, I expect will soon be shown to be far less effective than MAT 9001 in reducing triglycerides.
Also note that Matinas' market cap is only a fraction of that of Insmed whose primary product is an inhalable version of amphotericin b I expect will soon be shown to be more toxic, and less effective, than MAT 2202, which is an oral LNC version of this drug.
Led by a strong management team, I fully expect Matinas to trade at many multiples of its current SP in 2021.
LM
What other company has non-invasive band-aid type skin biopsies that are far more accurate than those performed with a scalpel?
Pourhassan could help restore his credibility, and stabilize the share price, by purchasing a large amount of stock in the open market.
Pourhassan can clearly afford to do this as he recently netted about $12 million from the sale of stock he received for free from the company.
If Pourhassan believed the share price is grossly undervalued, and should be in the triple digits, as he continually espouses, a million dollar-plus stock purchase should be a no brainer.
To those of you who believe Pourhassan did Cytodyn a favor by exercising options that netted him about $12 million, and everything he does is for the betterment of the company, to quote a prominent politician, "come on man."
LM
For those of you who voted for Pourhassan and Kelly to be gifted more stock, after Pourhassan previously netted around $12 million from his previous sale of gifted stock, and Kelly netted millions as well, perhaps you now realize the error of your ways.
For those of you who have thought, until now, that Pourhassan and Kelly were the proper team to lead this company, perhaps you now realize the error of your ways.
I have been a Cytodyn investor for about seven years, having participated in numerous Paulson raises.
Although I have held onto a sizeable part of my stock, I now realize the error of my ways.
I am convinced now, more than ever, that the company can succeed only if Pourhassan and Kelly are replaced with competent executives who know how to properly manage a company.
Best of luck to us all.
LM
Does anyone know if NASDAQ considers executive compensation, and the number of shares granted to company exeutives, in deciding whether to grant a listing?
If so, the past and impending share grants to Pourhassan would not bode well for Cytodyn being able to uplist to NASDAQ, in my opinion.
LM
I can't speak for Saltz, but I can tell you that many long term early Paulson investors appear to be disgusted with Pourhassan having received, and then sold, so many shares of company stock while again asking for a huge number of still more shares.
To me, at least, it is a very bad sign when the CEO is touting the stock as being grossly undervalued, while selling his own stock at the same time.
I am still holding a significant number of shares, so am hoping the shareholders vote no on awarding more stock to Pourhassan later this month.
LM
Does anyone know if NASDAQ considers executive compensation, and the number of shares granted to company executives, in deciding whether to grant a listing?
If so, the past and impending share grants to Pourhassan would not bode well for Cytodyn being able to uplist to NASDAQ, in my opinion.
LM
If Dockery prevails in his suit against Pourhassan, all of the proceeds will go to the company.
In other words, Dockery gets no recovery from his lawsuit, other than the benefit all shareholders get from Pourhassan having to return to the company the proceeds from his sale of some of his company stock.
LM
If you had any doubt before today's CC about how to vote on the share increase, executive compensation, or retention of directors, you should have no doubt now.
I am voting NO on every ballot measure as I believe now, more than ever, we we need to clean house.
For Leronlimab to succeed, we need competent management that is more interested in the shareholders than lining their pockets at the shareholder's expense.
LM
Brilliantly written, CT.
I would suggest you make this into a Seeking Alpha article.
LM
The share price can be stabilized by doing two simple acts:
Re-hire Bruce Patterson, and make him our official spokesperson; and
Announce that Pourhassan and Kelly have bought back all of the stock they sold, albeit at a much lower price that what they sold for.
Although replacing Pourhassan would be the ultimate elixir to our share price woes, in my opinion, I realize that is not going to realistically happen.
However, the other two acts, re-hiring Patterson, and Pourhassan/Kelly buying back the stock they sold, are definitely doable, and even Pourhassan should realize are desperately needed.
LM
In that I have been unable to confirm that Adam Feurstein wrote the email to Holly referred to in my previous postings on this board, I would advise against making any public comments about Adam Feurstein regarding this alleged email, or communicating with anyone regarding the same.
LM
Below is my email to Adam Feurstein, and his response:
Hello___ -- Thanks for reaching out. I don't comment on my ongoing reporting work.
Adam
On Mon, Aug 10, 2020 at 2:26 PM _____________ wrote:
Adam:
I have read on a message board that you sent an email to Olive, a person acting on behalf of Holly Kennedy, in which you stated as follows:
“Olive—I’m a reporter with STAT, a digital media company that covers health, medicine, and life sciences. I’m interested in speaking with you about Holly Kennedy and her decision to be treated with Leronlimab, despite any clinical evidence of efficacy in treating TNBC. Your posts suggest she’s been helped by Leronlimab, yet she was hospitalized soon after returning to Ireland. It seems like her condition has worsened, not improved. What evidence is there that Leronlimab has helped her? Do you know if Holly has pursued treatment with Trodelvy, for instance, which was recently approved in the US for advanced TNBC? Are you worried at all that you and Holly are being exploited by people promoting Leronlimab and Cytodyn for financial reasons? I’d like to speak with you if you have the time. Thank you—Adam Feurstein.”
As a STAT News subscriber, and Cytodyn shareholder, I have two questions for you:
First, did you in fact send this email?
Second, if you did send this email, what was the reason you did so?
I look forward to your prompt reply.
Thank you,
____
adam.feuerstein@statnews.com
I have sent an email to Adam Feurstein asking if he sent the email to Holly Kennedy's representative, Olive, referenced on this message board pertaining to her choice of Leronlimab as treatment for her TNBC.
I will post any response that I receive.
In the meantime, set forth above in what I believe to be Adam's email address.
So, please feel free to ask Adam yourself if he sent the email to Holly, and any other questions you have about it.
LM
On further reflection, before complaining to anyone about Feurstein's alleged communication to Holly, it is important to validate that he in fact sent the communication in question.
Perhaps someone could ask Feurstein directly.
LM
Stat News Owned by John W. Henry Owner of the Red Sox.
If you object to the writings of Adam Feurstein, you could, if you choose to do so, contact the owner of Stat News, which publishes Feurstein's articles.
Stat News is owned by John W. Henry, who also owns the Boston Globe, and the Boston Red Sox.
In my opinion, Mr. Henry would be appalled to known that a Stat News reporter had contacted a woman suffering from breast cancer, and attempted to convince her to stop using her chosen drug of choice.
This could prove to be very bad publicity for the Boston Red Sox.
So, in addition to writing directly to Mr. Henry about Feurstein, interested persons could also choose to write to the Red Sox, or on websites that cover the Red Sox, or sports in general.
Calls into sports talk shows could also be a possibility for spreading the word.
I am not advocating that anyone do any of these things.
However, complaining about Feurstein on message boards such as this is likely to have little impact.
LM
Here is the response I posted today in response to Adam Feurstein's short article on Cytodyn:
There you go again, for the tenth time, dissing Cytodyn.
You have been imploring your followers not to invest in Cytodyn, or to sell their holdings, during a time when the stock price ran up 1000%.
So whatever you are selling, the market isn't buying.
Your latest attack on Cytodyn is as unfounded and baseless as the nine that preceded it.
The Leronlimab safety results you call unimpressive were actually far superior to those of Remdesivir, the drug you (and Dr. Fauci) constantly tout.
Your main point of contention seems to be not so much that Leronlimab's Covid safety data is not impressive, which it clearly is, but that it was not accompanied by efficacy findings you claim were promised by CEO Pourhassan. From this, you deduce, the efficacy results must be bad or else they would have been disclosed.
However, as the company states in its press release, the efficacy data is being analyzed, and will soon be disclosed. Given that the data on 86 Covid patients was only unblinded this past Friday, two business days ago, it is unrealistic to expect a detailed analysis of the numerous efficacy endpoints at this early stage. As a long time biotech writer, I assume you know this.
Your supposition that the Leronlimab efficacy endpoints are too easy to meet, and pale in comparison to those in the Remdesivir trial, is not only wrong, but ignores the fact that when Remdesivir missed its primary endpoints, it changed them mid-trial. Thus, all of the Remdesivir endpoints you chide Cytodyn for not utilizing in its trial, such as supplemental oxygen, intubation, and mortality, were changed mid-trial to time to leave the hospital (an unimpressive savings of four days, for those patients who survived).
This change in primary endpoints was necessary because Remdesivir, an anti-viral, did not reduce the viral load in Covid patients, and, not surprisingly, had no benefit on mortality.
Leronlimab has proven, in treating over 65 seriously ill COVID patients at numerous well-respected hospitals including Montefiore and UCLA, who were administered this monoclonal antibody out of sheer desperation, that it is highly effective in saving lives.
If you don't believe me, just review the press releases from the treating physicians all of whom, along with Dr. Bruce Patterson, who analyzed the blood data, have lauded Leronlimab for both its safety and effectiveness. In fact, just last night Dr Patterson stated on Dr. Been's podcast (who you dismiss as a "You Tube Doctor), that Leronlimab is so effective in treating COVID that it should be "stockpiled."
So before you cause your short followers to lose even more money in betting against Cytodyn, I would suggest you do some real due diligence. Absent such diligence, your tenth short attack on Cytodyn could be your last.
Lawman
My response, published today on STAT, to Feuerstein's story on leronlimab:
This one-sided and completely slanted story leaves out important details such as the 60-plus patients treated with leronlimab on an emergency basis at prestigious hospitals, such as Montefiore, Novant, and UCLA, where the well-respected treating physicians, who administered leronlimab to their COVID-19 patients, attributed successful outcomes to this drug.
This story also leaves out the bloodwork analysis of leronlimab-treated COVID-19 patients by respected virologist Dr. Bruce Patterson, who claims leronlimab is the only drug that quells the cytokine storm, reduces the COVID-19 viral load, and helps restore the immune system in COVID-19 patients.
With respect to Nader Pourhassan's neutral comment that he cannot predict the outcome of ongoing COVID-19 clinical trials for leronlimab, no other credible answer was possible given that the trials are double-blinded, which is what Pourhassan correctly noted in his answer to this question.
Finally, it would be helpful to know whether you are short Cytodyn, which, if is the case, suggests a bias that should be disclosed.
LM
I could not agree with you more about the science, as well as Pourhassan.
I am especially troubled that Pourhassan recently sold stock that, after paying to exercise options, appears to have netted him about $12 million.
I am even more troubled that he intimated in interviews that he sold his stock to benefit the company without mentioning his personal financial gain.
The award of 6 million shares of stock if the company gets BTD for tmbc is even more appalling in my opinion.
I believe Pourhassan is more than fairly compensated with a compensation package worth about $1.6 million, and should not be getting an additional $18 million worth of stock for doing something that is part of his job duties as CEO.
So while I remain very high on the science, I continue to be extremely disappointed with Pourhassan.
Hope everyone is staying safe and healthy.
LM
I could not agree more BL.
Whoever writes Cytodyn's PR's is either not a gifted writer, or is trying to be intentionally vague and ambiguous.
Either way, we need to do much better on our PR's.
LM
I would gladly write CYDY's PR's for free.
Post a clear PR regarding Pourhassan's sale of stock.
Pourhassan’s muddled explanation regarding his sale of stock in today's Pro Active interview created more questions than answers, which, I believe, is why it had no positive effect upon the share price.
If Pourhassan sold his stock solely to pay for the exercise of options or warrants so the company would have enough money to pay Samsung to manufacture leronlimab, he should have said so.
Damage control is now needed in the form of a press release that should say something such as the following:
“The company wishes to clarify the reasons for the sale of Cytodyn stock by Dr. Nader Pourhassan on April___, 2020.
Although Dr. Pourhassan sold ___shares of Cytodyn stock at that time, 100% of the sale proceeds, in the amount of $_____, were used to pay for the exercise of Dr. Pourhassan’s options/warrants.
The proceeds paid to the company by Dr. Pourhassan, from the exercise of his options/warrants, will be used to pay Samsung Biologics to produce 1.2 million vials of leronlimab.
Without Dr. Pourhassan’s sale of stock and exercise of options/warrants, the company would not have been able to pay Samsung to manufacture leronlimab without a dilutive capital raise.”
My opinion, for what its worth.
LM
Does anyone know the names and email addresses of the reporters who appear at the President's daily press conferences?
How about the email address for Meg Tirell at CNBC, the fox anchors, and anyone else who covers the COVID-19 story for TV networks?
If so, please post these email addresses here.
I sent the following email to Governor Cuomo, and some other politicians and TV personalities who email addresses I was able to find:
Leronlimab, a late state drug developed by American pharmaceutical company Cytodyn, is BY FAR the most effective drug for treating COVID-19 patients.
Cytodyn today announced a patient at a leading Southern California hospital, who was treated for 4 days on other drugs, but ended up on life support, came off of life support, and is now healed, within days after being treated with Leronlimab.
Two of the other Socal CV patients were removed from oxygen soon after who being administered Leronlimab.
4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
For the good of the country, Leronlimab should be the treatment of choice for both mild to moderate and seriously ill CV patients.
Thank you.
LM
Below is an email I sent today to Nader Pourhassan:
Dr. Pourhassan:
I have previously written to you with suggestions as to how any future interviews can better present the success, to date, of Leronlimab.
To reiterate, I would respectfully offer the following:
As politicians do, any person being interviewed needs to script what he/she wants to say, and pivot from the question asked, and give such scripted answers.
In the four minutes you were interviewed by Charles Payne, for example, you could have been prepared to say, and pivoted to make the following points (which should, of course, be edited by you for accuracy):
1. 4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
2. The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
3. The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
4. In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
5. Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
If you make these comments, in response to whatever questions Charles Payne or any interviewer hereafter offers, the viewers would likely come away with a very favorable impression of Leronlimab.
In any future pre-interview with Payne, or any other interviewer, you might want to advise him/her of the above, so he/she would be able to ask questions that would be conducive to eliciting this information.
However, if the questions by Payne, or any future interviewer, are not phrased so as to elicit this information, I would respectfully suggest that you pivot, and provide this information, just as every politician pivots in responding to questions from reporters.
Thank you,
[Name Deleted]
Cytodyn Shareholder
Suggestions For Future Interviews: Pivot, Pivot, and Pivot again.
As politicians do, any person being interviewed needs to script what he/she wants to say, and pivot from the question asked, and give such scripted answers.
In the four minutes he was interviewed by Charles Payne, Pourhassan could and should have been prepared to say, and pivoted to say:
1. 4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
2. The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced by between 70 and 90 percent.
3. The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir. In other words, these 9 patients had better results after being treated with Leronlimab than they had with either hydroxychloride or remdesivir.
4. In over 800 patients who have been treated with Leronlimab over the past five years for HIV and metastatic breast cancer, there has not been one serious adverse event attributable to this drug.
5. Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients. Cytodyn expects to have at least some results for these trials within 30 days.
If Pourhassan had made these comments, in response to whatever questions Payne offered, the viewers would have come away with a much more favorable impression of Leronlimab.
If someone knows Charles Payne, they might want to advise him of the above, so he would be able to ask questions that would be conducive to eliciting this information.
However, if the questions by Payne, or any future interviewer, are not phrased so as to elicit this information, Pourhassan must pivot, and provide this information, just as every politician pivots in responding to questions from reporters.
LM
I am pleased this investment has turned out well for you.
Here's hoping for greater success in the future.
Best of luck to you.
LM
Agree completley, LD.
Hopefully, this was a learning lesson for Pourhassan.
LM
I am okay with "got off their ventilators."
But making clear that Leronlimab did this is what must be made clear in future interviews.
LM
Following is a message I sent today to Nader Pourhassan:
"Dr. Pourhassan:
The questions posed to you today by Charles Payne were not conducive to a good interview.
If faced with such unhelpful questions in another interview, I would respectfully suggest you pivot, and respond by providing the information you want to give.
So, for example, if you again get an opportunity to be interviewed on a national stage, or any television or radio interview for that matter, the first thing you should consider saying is something to this effect:
"Of the ____seriously ill COVID-19 patients who have been treated with Leronlimab, _____have extubated their ventilators within___days."
If you were to say this, and nothing else, you will have given a great interview.
Of course, you can also rattle off other bullet points such as:
1. In over 800 patients treated with Leronlimab, there has not been a single serious adverse event;
2. The FDA has approved leronlimab for two clinical trials; one for mild to moderately ill patients, and another for seriously ill patients;
3. The results of treating over___seriously ill COVID-19 patients have shown that the immune response is almost fully restored after seven days, and the cytokine storm has been reduced by as much as 70-90 percent in a matter of only a few days.
I hope this is helpful."
LM